antibody

MAb to Muc1

MBS312747

1 mg

575 USD

monoclonal

mouse

nonconjugated

[M2F1]

ELISA, immunohistochemistry - paraffin section, immunohistochemistry - frozen section

Antibody

MAb to Muc1

[Muc1 Glycoprotein]

[mucin glycoprotein; Mucin-1; mucin-1; episialin; DF3 antigen; H23 antigen; OTTHUMP00000033786; OTTHUMP00000033787; OTTHUMP00000033788; OTTHUMP00000033789; OTTHUMP00000033790; OTTHUMP00000033791; OTTHUMP00000033792; OTTHUMP00000033793; OTTHUMP00000033794; OTTHUMP00000033795; mucin 1, transmembrane; tumor-associated mucin; carcinoma-associated mucin; polymorphic epithelial mucin; peanut-reactive urinary mucin; tumor associated epithelial mucin; breast carcinoma-associated antigen DF3; tumor-associated epithelial membrane antigen; mucin 1, cell surface associated; Breast carcinoma-associated antigen DF3; Cancer antigen 15-3; CA 15-3; Carcinoma-associated mucin; Episialin; H23AG; Krebs von den Lungen-6; KL-6; PEMT; Peanut-reactive urinary mucin; PUM; Polymorphic epithelial mucin; PEM; Tumor-associated epithelial membrane antigen; EMA; Tumor-associated mucin; CD_antigen: CD227Cleaved into the following 2 chains:Mucin-1 subunit alpha; MUC1-NT; MUC1-alpha; Mucin-1 subunit beta; MUC1-betaAlternative name(s):MUC1-CT]

[Muc1]

[MUC1; MUC1; EMA; PEM; PUM; KL-6; MAM6; PEMT; CD227; H23AG; MUC-1; MUC-1/X; MUC1/ZD; MUC-1/SEC; PUM; MUC-1; CA 15-3; KL-6; PUM; PEM; EMA; MUC1-NT; MUC1-alpha; MUC1-beta]

MUC1_HUMAN

Monoclonal

IgG

[M2F1]

Mouse

Human

97

Binds with highly efficiency with different epitopes within the VNTR tandem repeat peptide region of MUC1 molecule. Efficiently recognizes underglycosylated and natural MUC1 protein isolated from human milk by affinity chromatography. Belongs to MAb clusters 6 & 7 according to ISOMB TD-4 classification. Does not cross react with normal serum proteins and human tissues of nonepithelial origin.

>90% pure (SDS-PAGE). Protein A chromatography

Purified, Liquid

8.4mg/ml (OD280nm, E^0.1% = 1.4)

Store at 2-8 degree C.

ELISA, Immunohistochemistry-Frozen/Paraffin, Paired Antibody

Can be used for immunohistochemical staining of paraffin and frozen sections. Can be used for staining of paraffin-embedded tissue sections fixed in neutral-buffered formalin and is compatible with commonly used histological fixatives. Can be used in the form of enzyme conjugate for development in ELISA sandwich assays of under-glycosylated tumor-associated MUC1 mucins in human serum. May be used in conjunction with MBS311553 and MBS311562 specific to unglycosylated VNTR region of MUC1 as the capture reagent.

Source: Ascites. Immunogen: High molecular weight (>300kDa) glycoprotein from human milk-fat globule molecule.

Buffer: PBS, pH 7.4. Preservative: 0.09% Sodium Azide

Monoclonal Antibodies for Cancer Research

MAb to MUC1. Monoclonal Antibody to Human MUC1 glycoprotein

4262069

P15941

IL-7 Signaling Pathway (198857); T Cell Receptor Signaling Pathway (198862)

This gene encodes a membrane-bound protein that is a member of the mucin family. Mucins are O-glycosylated proteins that play an essential role in forming protective mucous barriers on epithelial surfaces. These proteins also play a role in intracellular signaling. This protein is expressed on the apical surface of epithelial cells that line the mucosal surfaces of many different tissues including lung, breast stomach and pancreas. This protein is proteolytically cleaved into alpha and beta subunits that form a heterodimeric complex. The N-terminal alpha subunit functions in cell-adhesion and the C-terminal beta subunit is involved in cell signaling. Overexpression, aberrant intracellular localization, and changes in glycosylation of this protein have been associated with carcinomas. This gene is known to contain a highly polymorphic variable number tandem repeats (VNTR) domain. Alternate splicing results in multiple transcript variants.

Function: The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack. Ref.26 Ref.37 Ref.40 Ref.45 Ref.46 Ref.49 Ref.52 Ref.53 Ref.56The beta subunit contains a C-terminal domain which is involved in cell signaling, through phosphorylations and protein-protein interactions. Modulates signaling in ERK, SRC and NF-kappa-B pathways. In activated T-cells, influences directly or indirectly the Ras/MAPK pathway. Promotes tumor progression. Regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. Binds, together with KLF4, the PE21 promoter element of TP53 and represses TP53 activity. Ref.26 Ref.37 Ref.40 Ref.45 Ref.46 Ref.49 Ref.52 Ref.53 Ref.56. Subunit structure: The alpha subunit forms a tight, non-covalent heterodimeric complex with the proteolytically-released beta-subunit. Interaction, via the tandem repeat region, with domain 1 of ICAM1 is implicated in cell migration and metastases. Isoform 1 binds directly the SH2 domain of GRB2, and forms a MUC1/GRB2/SOS1 complex involved in RAS signaling. The cytoplasmic tail (MUC1CT) interacts with several proteins such as SRC, CTNNB1 and ERBs. Interaction with the SH2 domain of CSK decreases interaction with GSK3B. Interacts with CTNNB1/beta-catenin and JUP/gamma-catenin and promotes cell adhesion. Interaction with JUP/gamma-catenin is induced by heregulin. Binds PRKCD, ERBB2, ERBB3 and ERBB4. Heregulin (HRG) stimulates the interaction with ERBB2 and, to a much lesser extent, the interaction with ERBB3 and ERBB4. Interacts with P53 in response to DNA damage. Interacts with KLF4. Interacts with estrogen receptor alpha/ESR1, through its DNA-binding domain, and stimulates its transcription activity. Binds ADAM17. Ref.24 Ref.26 Ref.30 Ref.32 Ref.34 Ref.36 Ref.37 Ref.39 Ref.40 Ref.41 Ref.42 Ref.43 Ref.44 Ref.45 Ref.46 Ref.49 Ref.50 Ref.51 Ref.52 Ref.53 Ref.56. Subcellular location: Apical cell membrane; Single-pass type I membrane protein. Note: Exclusively located in the apical domain of the plasma membrane of highly polarized epithelial cells. After endocytosis, internalized and recycled to the cell membrane. Located to microvilli and to the tips of long filopodial protusions. Ref.33 Ref.42 Ref.43 Ref.44 Ref.48 Ref.50 Ref.52 Ref.54Isoform 5: Secreted Ref.33 Ref.42 Ref.43 Ref.44 Ref.48 Ref.50 Ref.52 Ref.54. Isoform 7: Secreted Ref.33 Ref.42 Ref.43 Ref.44 Ref.48 Ref.50 Ref.52 Ref.54. Isoform 9: Secreted Ref.33 Ref.42 Ref.43 Ref.44 Ref.48 Ref.50 Ref.52 Ref.54. Mucin-1 subunit beta: Cell membrane. Cytoplasm. Nucleus. Note: On EGF and PDGFRB stimulation, transported to the nucleus through interaction with CTNNB1, a process which is stimulated by phosphorylation. On HRG stimulation, colocalizes with JUP/gamma-catenin at the nucleus. Ref.33 Ref.42 Ref.43 Ref.44 Ref.48 Ref.50 Ref.52 Ref.54. Tissue specificity: Expressed on the apical surface of epithelial cells, especially of airway passages, breast and uterus. Also expressed in activated and unactivated T-cells. Overexpressed in epithelial tumors, such as breast or ovarian cancer and also in non-epithelial tumor cells. Isoform 7 is expressed in tumor cells only. Ref.9 Ref.49. Developmental stage: During fetal development, expressed at low levels in the colonic epithelium from 13 weeks of gestation. Ref.28. Post-translational modification: Highly glycosylated (N- and O-linked carbohydrates and sialic acid). O-glycosylated to a varying degree on serine and threonine residues within each tandem repeat, ranging from mono- to penta-glycosylation. The average density ranges from about 50% in human milk to over 90% in T47D breast cancer cells. Further sialylation occurs during recycling. Membrane-shed glycoproteins from kidney and breast cancer cells have preferentially sialyated core 1 structures, while secreted forms from the same tissues display mainly core 2 structures. The O-glycosylated content is overlapping in both these tissues with terminal fucose and galactose, 2- and 3-linked galactose, 3- and 3,6-linked GalNAc-ol and 4-linked GlcNAc predominating. Differentially O-glycosylated in breast carcinomas with 3,4-linked GlcNAc. N-glycosylation consists of high-mannose, acidic complex-type and hybrid glycans in the secreted form MUC1/SEC, and neutral complex-type in the transmembrane form, MUC1/TM. Ref.22 Ref.25 Ref.27 Ref.29 Ref.48 Ref.57Proteolytic cleavage in the SEA domain occurs in the endoplasmic reticulum by an autoproteolytic mechanism and requires the full-length SEA domain as well as requiring a Ser, Thr or Cys residue at the P + 1 site. Cleavage at this site also occurs on isoform MUC1/X but not on isoform MUC1/Y. Ectodomain shedding is mediated by ADAM17.Dual palmitoylation on cysteine residues in the CQC motif is required for recycling from endosomes back to the plasma membrane.Phosphorylated on tyrosines and serine residues in the C-terminal. Phosphorylation on tyrosines in the C-terminal increases the nuclear location of MUC1 and beta-catenin. Phosphorylation by PKC delta induces binding of MUC1 to beta-catenin/CTNNB1 and thus decreases the formation of the beta-catenin/E-cadherin complex. Src-mediated phosphorylation inhibits interaction with GSK3B. Src- and EGFR-mediated phosphorylation on Tyr-1229 increases binding to beta-catenin/CTNNB1. GSK3beta-mediated phosphorylation on Ser-1227 decreases this interaction but restores the formation of the beta-cadherin/E-cadherin complex. On T-cell receptor activation, phosphorylated by LCK. PDGFR-mediated phosphorylation increases nuclear colocalization of MUC1CT and CTNNB1. Ref.23 Ref.24 Ref.30 Ref.34 Ref.36 Ref.37 Ref.38 Ref.39 Ref.46 Ref.49 Ref.54 Ref.55The N-terminal sequence has been shown to begin at position 24 or 28 (Ref.20). Polymorphism: The number of repeats is highly polymorphic. It varies from 21 to 125 in the northern European population. The most frequent alleles contains 41 and 85 repeats. The tandemly repeated icosapeptide underlies polymorphism at three positions: PAPGSTAP[PAQT]AHGVTSAP[DT/ES]R, DT -> ES and the single replacements P -> A, P -> Q and P-> T. The most frequent replacement DT -> ES occurs in up to 50% of the repeats. Sequence similarities: Contains 1 SEA domain. Caution: O-glycosylation sites are annotated in first sequence repeat only. Residues at similar position are probably glycosylated in all repeats. Experimental sites were determined in a synthetic peptide glycosylated in vitro (Ref.25, Ref.29). Sequence caution: The sequence AAD14369.1 differs from that shown. Reason: Erroneous initiation. The sequence AAD14376.1 differs from that shown. Reason: Erroneous initiation.

1 mg

575 USD